13F Pro13F Pro

Vestal Point Capital, LP

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1974915
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare100.0%$4.3B

AUM History

13fpro.ai/research/fund/vestal-point-capital-lp-1974915

Conviction and streaks

Concentrating · top 10 = 50.3%

From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.

BMRN$BMRNConviction hold8.1% weight · held 5 quartersABVX$ABVXConviction hold7.3% weight · held 4 quartersELVN$ELVNConviction hold4.7% weight · held 5 quartersNRIX$NRIXConviction hold4.6% weight · held 7 quartersBCAX$BCAXConviction hold3.6% weight · held 7 quartersNRIX$NRIXAccumulating+1560% shares · 6 quarters runningBMRN$BMRNAccumulating+1105% shares · 4 quarters runningTSHA$TSHAAccumulating+547% shares · 4 quarters runningABT$ABTAccumulating+700% shares · 3 quarters runningZBH$ZBHAccumulating+2700% shares · 3 quarters runningNYXH$NYXHTrimming-71% shares · 6 quarters runningALC$ALCTrimming-55% shares · 2 quarters runningSLDB$SLDBTrimming-63% shares · 2 quarters runningANRO$ANROTrimming-68% shares · 2 quarters runningOLMA$OLMATrimming-75% shares · 2 quarters running

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/vestal-point-capital-lp-1974915

Vestal Point Capital, LP 13F holdings — Q2 2026

$4.3B portfolio (+19.6% QoQ) · 68 holdings · Q2 2026 13F · top 10 are 50% of the stock portfolio

All holdings — Vestal Point Capital, LP (Q2 2026)

68 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
ZBH$ZBHZIMMER BIOMET HOLDINGS, INC.$120.5M+637%
IRON$IRONDisc Medicine, Inc.$113.4M+121%
GLUE$GLUEMonte Rosa Therapeutics, Inc.$111.3M+28%
PODD$PODDINSULET CORP$102.0M+1224%
ASND$ASNDAscendis Pharma A/S$100.0M—
AZN$AZNASTRAZENECA PLC$85.3M+350%
SNY$SNYSanofiadr$85.3M+43%
RVMD$RVMDRevolution Medicines, Inc.$84.3M-81%
BCRX$BCRXBIOCRYST PHARMACEUTICALS INC$83.0M+18%
DYN$DYNDyne Therapeutics, Inc.$75.0M-16%
NKTR$NKTRNEKTAR THERAPEUTICS$69.8M+251%
GMED$GMEDGLOBUS MEDICAL INC$67.2M+39%
TARS$TARSTarsus Pharmaceuticals, Inc.$66.1M+425%
IMTX$IMTXImmatics N.V.$62.6M—
TRVI$TRVITrevi Therapeutics, Inc.$57.8M+43%

What changed in Q2 2026

Against the previous quarter's 13F: 9 new, 31 added to, 22 trimmed, 31 sold out. Share-count changes; largest moves by dollar size first.

New positions (9)

  • ABT$ABTABBOTT LABORATORIES$127.0M

    first bought this quarter

  • INSM$INSMINSMED Inc$26.7M

    first bought this quarter

  • TRAX$TRAXFirst Tracks Biotherapeutics, Inc.$20.4M

    first bought this quarter

  • AVTX$AVTXAvalo Therapeutics, Inc.$14.3M

    first bought this quarter

  • EVMN$EVMNEvommune, Inc.$13.3M

    first bought this quarter

  • KLRA$KLRAKailera Therapeutics, Inc.$12.7M

    first bought this quarter

+3 more in the Excel export

Added to (31)

  • UTHR$UTHRUNITED THERAPEUTICS Corp+480%

    now $235.7M · held 2 qtrs, 2 adds in a row

  • BMRN$BMRNBIOMARIN PHARMACEUTICAL INC+69%

    now $344.8M · held 5 qtrs, 5 adds in a row

  • ABVX$ABVXAbivax S.A.+57%

    now $313.1M · held 4 qtrs

  • NBIX$NBIXNEUROCRINE BIOSCIENCES INC+50%

    now $316.8M · held 2 qtrs, 2 adds in a row

  • ZBH$ZBHZIMMER BIOMET HOLDINGS, INC.+637%

    now $120.5M · held 3 qtrs, 3 adds in a row

  • PODD$PODDINSULET CORP+1224%

    now $102.0M · held 2 qtrs, 2 adds in a row

+25 more in the Excel export

Trimmed (22)

  • RVMD$RVMDRevolution Medicines, Inc.-81%

    now $84.3M · held 5 qtrs

  • RGEN$RGENREPLIGEN CORP-57%

    now $54.6M · held 4 qtrs

  • ARWR$ARWRARROWHEAD PHARMACEUTICALS, INC.-31%

    now $128.4M · held 3 qtrs

  • ANRO$ANROAlto Neuroscience, Inc.-62%

    now $20.7M · held 7+ qtrs, 2 trims in a row

  • IMCR$IMCRImmunocore Holdings plc-35%

    now $57.1M · held 3 qtrs

  • RAPP$RAPPRapport Therapeutics, Inc.-49%

    now $30.4M · held 4 qtrs

+16 more in the Excel export

Sold out (31)

  • APGE$APGEApogee Therapeutics, Inc.was $92.6M

    held 3 qtrs

  • SRRK$SRRKScholar Rock Holding Corpwas $65.1M

    held 5 qtrs

  • VERA$VERAVera Therapeutics, Inc.was $55.0M

    held 6+ qtrs

  • TERN$TERNTerns Pharmaceuticals, Inc.was $52.7M

    held 2 qtrs

  • BSX$BSXBOSTON SCIENTIFIC CORPwas $50.2M
  • NUVL$NUVLNuvalent, Inc.was $49.4M

+25 more in the Excel export

Firm AUM (Form ADV): $5.5B as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F Vestal Point Capital, LP has filed, 10 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow Vestal Point Capital?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of Vestal Point Capital's top 20 holdings: 52/100 (our AI quality score, weighted by position size; 12 of the 20 are scored)

Top 10 since filing

-15.1%

Value-weighted move of the 10 largest stock positions

Turnover

37%

Last quarter; 161% over the last 4

Top 10 weight

50%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

53%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q4 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

Vestal Point Capital, LP disclosed 68 positions worth $4.3B in its Form 13F-HR for Q2 2026, led by $BMRN (BIOMARIN PHARMACEUTICAL INC) at 8.1% of the equity portfolio, followed by $NBIX and $ABVX. During the quarter the fund opened 9 new positions and exited 31 — including a new stake in $ABT and a full exit from $APGE. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Vestal Point Capital, LP’s Form 13F-HR filing with the SEC under CIK 1974915.

Funds like this

managers whose biggest positions overlap Vestal Point Capital's
Avoro Capital Advisors LLC$11.14B 13F book · 7 shared top holdingsUTHRARWRRVMDTSHATCG Crossover Management, LLC$4.16B 13F book · 6 shared top holdingsABVXGLUEIRONBCRXSiren, L.L.C.$4.94B 13F book · 9 shared top holdingsBCAXARWRRVMDELVNDIADEMA PARTNERS LP$791.35M 13F book · 10 shared top holdingsABVXUTHRBMRNRVMDFirst Turn Management, LLC$934.72M 13F book · 7 shared top holdingsABVXUTHRELVNRVMDLogos Global Management LP$2.32B 13F book · 9 shared top holdingsABVXIRONRVMDDYN

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: Vestal Point Capital, LP

13F Pro is an AI hedge fund tracker and stock research platform. For Vestal Point Capital, LP (SEC CIK: 1974915), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in Vestal Point Capital, LP's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.